Psoriatic arthritis
sheila RHEUMarampa
1 week 1 day ago
The CLASSIC study validated the performance of the 2009 ASAS classification criteria
Model A was chosen for the revised criteria since it achieved prespecified performance targets of SN ≥75% and SP ≥90%
🔸Pso was included
🔸⬆️CRP replaced dactylitis
#ACR25 @RheumNow Abs0854 https://t.co/tK52rQyaRa
Antoni Chan MD (Prof) synovialjoints
1 week 1 day ago
In a global retrospective study of 90,536 PsA patients, those on GLP-1 receptor agonists (n=4,104) had significantly lower risk of major cardiovascular events and reduced mortality vs non-users. Most common GLP-1 RA: semaglutide. Supports future research on cardiometabolic https://t.co/ccOL10gD5b
Mrinalini Dey DrMiniDey
1 week 1 day ago
Time for the 2nd plenary session! 🎤
#0849 GLP-1 receptor agonists in #PsA linked with lower mortality & fewer major cardiac events in >90K patients.
Promising data for inflammation, weight & heart health in PsA care. @RheumNow #ACR25 https://t.co/8zyrSrumOP
David Liew drdavidliew
1 week 1 day ago
This morning in the plenary, same theme, but in PsA:
Similar metabolic/CV concerns
Similarly benefit from GLP-1 RA
looking at TriNetX data again, reduced MACE
Now prospective trials in rheum disease, for both metabolic benefits & disease activity?
#ACR25 ABST0849 @RheumNow https://t.co/DHZN1hwbIG
The GLP-1 story has been hard to miss this year, and at ACR Convergence, it’s clear that these drugs are starting to make real waves in rheumatology. Across multiple abstracts, investigators have used a large real-world dataset, the TriNetX network, to explore how GLP-1 receptor agonists (GLP-1RAs) might influence cardiovascular, renal and immune-mediated outcomes in our patients.
Antoni Chan MD (Prof) synovialjoints
1 week 2 days ago
Increased risk of psoriatic arthritis with obesity. A preview to Abstract#2687 Scher J @RheumNow #ACR25 https://t.co/cMbrQnq8YG
Aurelie Najm AurelieRheumo
1 week 2 days ago
High prevalence of sleep related symptoms in PsA pts!
-Snoring 53%
-Morning fatigue 68%
-Obstructive Sleep Apnea in 50%
14% mild 19% moderate 17% severe
Estimated prevalence 36%
No correlation between OSA and PsA disease activity or comorbidities
But small cohort! https://t.co/VKe7qcHIRm
sheila RHEUMarampa
1 week 2 days ago
Dr. Ogdie on emerging PsA tx:
“It’s not just about the pharmacotherapy but also about making the patient feel better”
Also, weight loss is incredibly important but also incredibly hard. Losing weight is more impt than the type of diet a patient should be on.
#ACR25 @RheumNow https://t.co/FN3EEowkDP
sheila RHEUMarampa
1 week 2 days ago
Why do we need to identify early PsA?
🔅Improve symptoms
🔅Prevent radiographic progression
🔅Preserve function
☝️Recent data show that erosions are prevalent in early PsA but lower if symptom duration is <6 mos.
#ACR25 @RheumNow https://t.co/sEGXzd8RiD
sheila RHEUMarampa
1 week 2 days ago
What are the RFs for progression of Pso to PsA?
🔸PsO disease severity - 3.2x risk —>PsA
🔸Phenotype - nail involvement
🔸Obesity - 6x higher risk of developing PsA
🔸MSK symptoms - arthralgia & heel pain
#ACR25 @RheumNow https://t.co/UPXuxBPyKI
Antoni Chan MD (Prof) synovialjoints
1 week 2 days ago
The severity of skin psoriasis increases the risk of psoriatic arthritis. Scher J @RheumNow #ACR25 https://t.co/EI0ACWACHy
David Liew drdavidliew
1 week 2 days ago
Trying to reach RA, PsA patients on social media, to participate in studies?
Simple, informational messages work for recruitment
Message framing affects engagement but not recruitment
The more we understand, the better we can reach the right people
#ACR25 ABST0187 @RheumNow https://t.co/JoAthXhXvi
Aurelie Najm AurelieRheumo
1 week 2 days ago
A simple flow cytometry analysis of peripheral blood monocytes to predicts progression to clinical RA or PsA in at-risk patients?
Too good to be true!
284 RA 56 PsA 57 HC
-HLA-DR higher in PsA
-CD11c lower in RA
But no clear difference between Converters and non Converters https://t.co/f3Sett4eXd
Antoni Chan MD (Prof) synovialjoints
1 week 2 days ago
PD-1+ effector memory T cells in PsA synovium are functionally active and regulate Th17 cytokines via STAT3/RORγt. Recombinant PD-L1 agonist significantly reduced T cell proliferation and IL-17A/F/IL-22 production highlighting checkpoint agonists as a novel therapeutic strategy https://t.co/I6eNa0j7aa
Poster Hall